Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

OBJECTIVE: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. METHODS: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Levy, Roger A, Cervera, Ricard, Petri, Michelle A, Birch, Helen, Freimuth, William W, Zhong, Z John, Clarke, Ann E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995218/
https://www.ncbi.nlm.nih.gov/pubmed/23524886
http://dx.doi.org/10.1136/annrheumdis-2012-202865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995218/
https://www.ncbi.nlm.nih.gov/pubmed/23524886
http://dx.doi.org/10.1136/annrheumdis-2012-202865

Ejemplares similares